AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00637832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT00637832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00637832 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT01329588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Monthly placebo
Description: Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03065478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: OnLife
Description: Daily dosing of dietary supplement OnLife
Study NCT01834768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study NCT02296203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT02296203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study NCT03758703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-recorded music intervention group
Description: Refer to the arm/group descriptions.
Study NCT03758703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-recorded soothing poetry group
Description: Refer to the arm/group descriptions.
Study NCT03488225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT03488225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV or PO
Study NCT03488225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03488225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03488225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02570672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
Study NCT02570672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will randomized to placebo will receive placebo
Study NCT02561741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study NCT04364464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet
Study NCT01879033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reactive hyperemia peripheral artery tonometry (Rh-PAT)
Description: Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
Study NCT01879033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reactive hyperemia peripheral artery tonometry (Rh-PAT)
Description: Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
Study NCT01879033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood levels for glucose, insulin, lipids and adipocytokines
Description: A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
Study NCT01879033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood levels for glucose, insulin, lipids and adipocytokines
Description: A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
Study NCT03490396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelclair
Description: Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
Study NCT03490396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelclair
Description: Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
Study NCT02664025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal examination simulator
Study NCT02747719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light and exercise
Description: Exposure to light and exercise
Study NCT03490396 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: First® Mouthwash BLM
Description: Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
Study NCT01500967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shi-style cervical manipulations
Description: Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
Study NCT01500967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction control
Description: 6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
Study NCT02538692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tong-Xie-Yao-Fang
Description: Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
Study NCT02538692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is the same as Tong-Xie-Yao-Fang in appearance.
Study NCT03871725 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy (SDT)
Description: Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
Study NCT02860117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine continuous infusion
Description: Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
Study NCT02860117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous infusion (0,2 ml/kg/h)
Study NCT02271711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01820221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture vs. staples closure method after c-section in obese women.
Description: Random card draw to either suture skin closure or staple skin closure arm of study.
Study NCT02271711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given autologous ex-vivo expanded NK cells IV
Study NCT04326439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m²/dose every 12 hours IV Days 1-10
Study NCT04326439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 50 mg/m²/dose IV Days 1, 3, 5
Study NCT04326439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: 25,000 International Units/m²/dose IM Days 2, 9
Study NCT04326439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m²/dose IV Days 1-5
Study NCT04326439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
Study NCT04326439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Description: Transplantation of multipotent hematopoietic stem cells from bone marrow
Study NCT04326439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
Study NCT03493022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Granola
Description: 50.5 Test Granola
Study NCT03493022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Granola
Description: 54.3 Control Granola
Study NCT05616429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcat based personal diet
Description: Alcat based personalized diet with dietician supervision and follow-up + usual care
Study NCT05616429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard balanced diet
Description: Sham standard balanced diet with dietician supervision and follow up + usual care.
Study NCT05616429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual care
Study NCT05616429 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: usual care
Study NCT01537276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnose under real-time fluoroscopy
Description: radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
Study NCT01242501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.
Description: Single session risk reduction counseling delivered in STI clinic settings in South Africa.
Study NCT01242501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-Min education session
Description: Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
Study NCT04336852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilation (brachial and femoral arteries)
Description: Assessment of vascular function of the brachial and femoral arteries.
Study NCT04336852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral vascular reactivity to carbon dioxide (CO2)
Description: Cerebral blood flow responses to increasing partial pressure of CO2
Study NCT04336852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral vascular function test
Description: Cerebral blood flow responses to a reactive hyperemia stimulus
Study NCT01909726 — intervention group
Intervention type: OTHER
Intervention: ScreenPlay
Description: Interactive technology
Study NCT03903367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
Study NCT04151238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention for cancer patients to increase physical activity during chemotherapy
Description: The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
Study NCT03516006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: infusion of aUCMSC at day 0, 7, 14, and 21
Study NCT03516006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
Study NCT03516006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
Study NCT00314132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE, Japanese Encephalitis vaccine
Description: 0.5 mL, Subcutaneous
Study NCT00314132 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: 0.5 mL, Subcutaneous
Study NCT03602794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECs Block
Description: Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance
Study NCT03602794 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local infiltration
Description: LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
Study NCT03972397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Cryoablation
Description: Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
Study NCT03972397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposomal injectable suspension
Description: Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
Study NCT03972397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposomal injectable suspension
Description: Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
Study NCT03972397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Description: Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
Study NCT03972397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Description: Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
Study NCT03068221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anaerobic exercise
Description: assessing anaerobic exercise status
Study NCT02440737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook.
Study NCT02440737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up Care
Description: Complete Survivorship Care Planning session at end of treatment
Study NCT02440737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Undergo the NEST intervention
Study NCT02440737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02154477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: insulin
Study NCT02154477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo (intranasal saline)
Description: saline
Study NCT05008263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver elastography (2D-SWE)
Description: All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
Study NCT05008263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver scintigraphy with 99mTc-mebrofenin
Description: All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
Study NCT01037413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXC 001
Description: Multiple intradermal injections of EXC 001 and placebo
Study NCT01037413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple intradermal injections of EXC 001 and placebo
Study NCT02934542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLap system
Study NCT04550286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Use Reduction in Academic Context
Description: Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013).